The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial launch on ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a new autoinjector pen option for Cyltezo, an interchangeable biosimilar to Humira. Cyltezo ...

Humira (adalimumab) is a prescription drug used for various conditions, including rheumatoid arthritis and plaque psoriasis. Mild side effects of the drug include injection site reactions, headache, ...

Q: I take Humira Pen injections every two weeks. I need to find out how to dispose of the needles. L.B. A: Humira’s manufacturer AbbVie offers a free Sharps Mail-Back program to all patients taking ...